EXAGEN INC. (68) | Business Finance (27)

Browse by Subcategory

Recent Contracts

Underwriting Agreement, dated March 22, 2021, by and among Exagen Inc. and Cowen and Company, LLC, William Blair & Company, L.L.C. and Cantor Fitzgerald & Co., as representatives... (Filed With SEC on March 23, 2021)
Acknowledgement Letter to Loan and Security Agreement, by and between Innovatus Life Sciences Lending I, LP and the Registrant (Filed With SEC on November 10, 2020)
Exagen Inc. 2019 Employee Stock Purchase Plan (Filed With SEC on September 9, 2019)
Amendment No. One to Asset Purchase Agreement, dated March 10, 2011, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant (Filed With SEC on August 23, 2019)
Amended and Restated Investors Rights Agreement, dated July 12, 2019, by and among the Registrant and certain of its stockholders (Filed With SEC on August 23, 2019)
Form of Warrant to Purchase Shares of Preferred Stock issued to investors by the Registrant in October 2015 (Filed With SEC on August 23, 2019)
Amendment to Convertible Promissory Notes and Warrants, dated January 19, 2016 (Filed With SEC on August 23, 2019)
First Amendment to Loan and Security Agreement with Innovatus Life Sciences Lending I, LP dated November 19, 2019 (Filed With SEC on March 25, 2020)
Specimen stock certificate evidencing the shares of common stock (Filed With SEC on September 9, 2019)
Form of Preferred Stock Purchase Warrant issued to Capital Royalty Partners and related advisors by the Registrant in connection with the Term Loan Agreement, by and between... (Filed With SEC on August 23, 2019)
Form of Underwriting Agreement (Filed With SEC on August 23, 2019)
Loan and Security Agreement, dated September 7, 2017, by and between Innovatus Life Sciences Lending Fund I, LP and the Registrant (Filed With SEC on August 23, 2019)
Amendment No. Six to Asset Purchase Agreement, dated February 16, 2017, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant (Filed With SEC on August 23, 2019)
Amendment No. Five to Asset Purchase Agreement, dated January 26, 2016, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant (Filed With SEC on August 23, 2019)
Amendment No. Four to Asset Purchase Agreement, dated October 8, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant (Filed With SEC on August 23, 2019)
Amendment No. Three to Asset Purchase Agreement, dated February 6, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant (Filed With SEC on August 23, 2019)
Amendment No. Two to Asset Purchase Agreement, dated August 21, 2012, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant (Filed With SEC on August 23, 2019)
Asset Purchase Agreement, dated October 8, 2010, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant (Filed With SEC on August 23, 2019)
Amendment No. Two to Asset Purchase Agreement, dated January 11, 2017, by and between the Registrant and Cellatope Corporation (Filed With SEC on August 23, 2019)
Amendment No. One to Asset Purchase Agreement, dated December 14, 2012, by and between the Registrant and Cellatope Corporation (Filed With SEC on August 23, 2019)
Form of Common Stock Purchase Warrant issued to investors by the Registrant in connection with private placement financings (Filed With SEC on August 23, 2019)
Exagen Inc. 2019 Employee Stock Purchase Plan (Filed With SEC on August 23, 2019)
Exagen Diagnostics, Inc. 2013 Stock Option Plan, as amended, and form of option agreement thereunder (Filed With SEC on August 23, 2019)
Exagen Corporation 2002 Stock Option Plan, as amended, and form of option agreement thereunder (Filed With SEC on August 23, 2019)
Form of Warrant to Purchase Stock issued to Innovatus Life Sciences Lending Fund I, LP in connection with the Registrants 2018 loan agreement (Filed With SEC on August 23, 2019)
Form of Common Stock Purchase Warrant to purchase common stock issued to investors by the Registrant in 2016 (Filed With SEC on August 23, 2019)
Asset Purchase Agreement, dated February 9, 2009, by and between the Registrant (as successor in interest to Cypress Bioscience, Inc.) and Cellatope Corporation (Filed With SEC on August 23, 2019)